11/3/2026

speaker
Conference Operator
Operator

Good day, ladies and gentlemen, and welcome to the Compass Pathways third quarter 2026 conference call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Stephen Schultz. You may begin.

speaker
Steve Schultz
Senior Vice President, Investor Relations, Compass Pathways

Welcome, all of you, and thank you for joining us today for this conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways. and today I'm joined by Kabir Nath, our Chief Executive Officer, and Lori Englebert, our Chief Commercial Officer. Dr. Steve Levine, our Chief Patient Officer, and Teri Loxam, our Chief Financial Officer, will also be available for the Q&A. The call is being recorded and will be available on the Compass Pathways Investor Relations website shortly after the conclusion of the call and will be available for a period of 30 days. Before we begin, let me remind everyone that during the call today, we will be making statements about our future plans and prospects that constitute forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement, including those risks and uncertainties described under the heading Risk Factors in our most recent filings with the U.S. Securities and Exchange Commission. These forward-looking statements represent our views only as of today, and we specifically disclaim any obligation to update or revise any forward-looking statement, even if our estimates or assumptions change. I will now hand the call to Kabir Nath.

speaker
Kabir Nath
Chief Executive Officer, Compass Pathways

Thank you, Steve, and thank you all for joining us today. Compass continues to make excellent progress toward the potential FDA approval of our psychedelic treatment, which will fundamentally change How Mental Health is Managed. Today, for the estimated 4 million individuals in the US who are impacted by treatment-resistant depression, there is only one approved and marketed drug with that indication, and fewer than 3% of those patients are actually being treated with it. Comp360's profile is unique and compellingly differentiated in delivering both a rapid onset with effects seen within 24 hours, and durability potentially up to 12 months with just a few treatments. The data also show a safety profile that's generally well tolerated. We're confident that Comp360's efficacy in this difficult to treat patient population, along with a much less frequent administration schedule, will be highly attractive to patients and prescribers, a confidence that's been well supported by the recent market research that we've been conducting. We will complete our rolling NDA submission in the next two weeks. We have ensured that the filing is the highest quality with two highly statistically significant phase three studies together with a positive phase two B study that together enrolled over a thousand patients. This will enable the agency to review it with its usual scientific rigor. Given that this has been a rolling submission and because we've been granted a national priority voucher The ongoing interactions with the FDA remain productive with a high level of constructive engagement between our respective teams. The voucher sets a one to two month review target for the FDA. So there's the potential for a very rapid approval. Our commercial preparations are moving forward with tremendous momentum. Lori has assembled an all-star team that has the expertise and experience to introduce Comp360 and deliver a successful launch following the potential approval of the TRD indication. Our late stage trial for post-traumatic stress disorder or PTSD, which is designed to be registrational, is actively enrolling. PTSD represents an important labor expansion opportunity for Comp360. Over 13 million adults in the US are affected by PTSD and the only approved medicines are two drugs that were approved over 25 years ago, which offer limited effectiveness. Given our robust and strong patent portfolio for Comp360, we're also exploring several other opportunities to expand the label. With our demonstrated success in clinical development for this class of medicines and the ability to leverage the commercial infrastructure we're building, we envisage multiple potential future indications. This could drive tremendous long-term revenue and earnings growth for the company, well beyond TRD and PTSD. For now, our priority remains completely focused on maximizing the 2027 launch of Comp360 and TRD. We expect our strong balance sheet with $444 million of cash on hand as of September the 30th to carry us well through the launch and into 2028. Let me now hand the call to Lori to provide more detail on our commercial strategy and set the stage for some of the key parameters we will be using to evaluate the launch as it progresses through the course of 2027. Lori?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation